TNFRSF10B and brain neoplasm: Using subcutaneous brain tumor mouse models, we consistently showed that in vivo lovastatin treatment also induced DR5 expression in the tumor tissue and inhibited tumor growth; importantly combined treatment with lovastatin and TRAIL resulted in synergistic effects that does not only inhibit tumor growth, reduce tumor volume, but also inhibit Erk activation in U87 cell line.